Summary
- Profile Type
- Technology offer
- POD Reference
- TOGB20250410020
- Term of Validity
- 10 April 2025 - 10 April 2026
- Company's Country
- United Kingdom
- Type of partnership
- Investment agreement
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
-
The UK SME is developing technologies for targeting lipid nanoparticles (LNPs) to specific cell types. Their solution blocks non-specific uptake and re-directs to specific cells to provide targeted drug delivery.
The company is seeking:
• Strategic collaboration with drug developers under a commercial agreement with technical assistance in order to demonstrate their technology for therapeutic applications.
• Investment to further develop the technology. - Full Description
-
A UK-based biotech SME is developing technologies for targeting lipid nanoparticles (LNPs) to specific cell types.
LNPs are promising drug delivery vehicles for delivering myriad therapeutics, including nucleic acids (DNA, mRNA, siRNA ), proteins, antibodies, vaccines, gene editing components (e.g. CRISPR) .
However, LNPs accumulate in the liver due to proteins from the blood fouling on the LNP surface, forming a ‘protein corona’ that triggers uptake in liver cells (hepatocytes).
The company has developed a technology that can block uptake in liver cells whilst also providing antibody-mediated targeting, enabling specific delivery to target cells. The technology has been validated in vitro and in vivo.
The company is now seeking opportunities to demonstrate its targeting technology for therapeutic applications through strategic partnerships with drug developers under a commercial agreement with technical assistance
A partner would provide a therapeutic agent to be delivered and a model system that it can be tested with, whilst the UK company would provide a targeting agent and optionally the LNPs.
The data gathered will be leveraged by the company to raise further investment for further development of the technology - Advantages and Innovations
-
The lipid nanoparticle (LNP) targeting technologies have the following advantages:
• Targeted delivery of LNPs to specific cell types
• Significantly reduced uptake in non-target cells
• The targeting agent is simple to apply. It can be applied to LNPs in minutes at high-throughput, and requires no special equipment or expertise
• The targeting technology is agnostic to LNP formulation. It can be applied to most typical formulations
• The technology can be tailored for different cell types and/or applications. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
Partner Sought
- Expected Role of a Partner
-
Partners will operate in the biotechnology, pharmaceuticals and healthcare sectors.
The potential partner should:
• Have a therapeutic agent suitable for delivery via LNP, e.g. nucleic acids (DNA, mRNA, siRNA), proteins, antibodies, vaccines, gene editing components (e.g. CRISPR), that would benefit from targeting a specific cell type.
• Have a system for testing successful delivery of the therapeutic agent that either contains multiple cell types or is an in vivo model.
• Have expertise in the relevant therapeutic area.
We expect the partner to either:
• Provide their therapeutic agent and expertise to the company with the company providing the testing of the agent in a targeted LNP; or
• Use their own system to test LNP (optionally provided by the company) coated with the company’s targeting technology and containing their therapeutic agent.
The desired outcome is a data package demonstrating the successful delivery of an LNP-encapsulated therapeutic agent to a specific cell type - Type and Size of Partner
- Other
- SME 50 - 249
- University
- R&D Institution
- Big company
- SME <=10
- SME 11-49
- Type of partnership
- Investment agreement
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06001012 - Medical Research
- 06001002 - Clinical Research, Trials
- 06002004 - Protein Engineering
- 06001015 - Pharmaceutical Products / Drugs
- 06002002 - Cellular and Molecular Biology
- Market keywords
- 05003006 - Other therapeutic (including defibrillators)
- 05003005 - Drug delivery and other equipment
- 05005022 - Other clinical medicine
- 05007002 - Pharmaceuticals/fine chemicals
- Sector Groups Involved
- Health
- Targeted countries
- All countries